CoChat

Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid‐cycling disease course: a randomized, double‐blind, placebo‐controlled study

Vieta, E, Calabrese, JR, Goikolea, JM, Raines, S, Macfadden, W, for the BOLDER Study Group · 2007 · Bipolar Disorders
Cited by 110

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Objectives: To investigate the efficacy and tolerability of quetiapine monotherapy in patients with bipolar I or II disorder with a rapid‐cycling disease course. Methods: Adult patients with a DSM‐IV diagnosis of bipolar disorder, most recent episode depressed, with a rapid‐cycling disease course from a previously completed multicenter trial randomized to 8 weeks of treatment with quetiapine 600 mg/day (n = 31), quetiapine 300 mg/day (n = 42), or placebo (n = 35) were included in this sub‐analysis. The primary efficacy variable was change from baseline to week 8 in Montgomery–Asberg Depression Rating Scale (MADRS) total score. Results: Quetiapine (600 and 300 mg/day) provided significantly greater mean reductions from baseline to week 8 in the MADRS total score than placebo (−21.1, −20.7 versus −11.6, both p < 0.001) in this patient population. Effect sizes in patients with a rapid‐cycling disease course were 1.2 (600 mg/day) and 1.1 (300 mg/day) and were similar for bipolar I (0.98 and 1.22) and bipolar II (1.45 and 0.97) sub‐groups. Significant improvements were also noted on the Clinical Global Impression, Hamilton Rating Scale for Depression, Hamilton Rating Scale for Anxiety, Pittsburgh Sleep Quality Index, and Quality of Life Enjoyment and Satisfaction Questionnaire scales. Quetiapine was generally well tolerated with moderate increases in weight and extrapyramidal side effects compared to placebo. The incidence of treatment‐emergent mania was similar to placebo. Conclusions: Quetiapine monotherapy (600 or 300 mg/day) is clinically effective and well tolerated in the short‐term treatment of depressive episodes in patients with bipolar I or II disorder who have a rapid‐cycling disease course.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1399-5618.2007.00479.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 110

Metadata

Authors
Vieta, E., Calabrese, Jr., Goikolea, J., Raines, S., Macfadden, W., & for the BOLDER Study Group
Venue
Bipolar Disorders
Publisher
Wiley
Published
2007-06
Volume
9
Issue
4
Pages
413-425
ISSN
  • 1398-5647 (ISSN-L)
  • 1399-5618
OpenAlex
W2122710476
Cited by
110
References
7
FWCI
7.28
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid‐cycling disease course: a randomized, double‐blind, placebo‐controlled study. https://app.cochat.ai/papers/10.1111/j.1399-5618.2007.00479.x
The paper
Vieta, E., Calabrese, Jr., Goikolea, J., Raines, S., Macfadden, W., & for the BOLDER Study Group. (2007). Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid‐cycling disease course: a randomized, double‐blind, placebo‐controlled study. Bipolar Disorders. https://doi.org/10.1111/j.1399-5618.2007.00479.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.